The latest price target for PTC Therapeutics (NASDAQ:PTCT) was reported by Jefferies on March 30, 2026. The analyst firm set a price target for $76.00 expecting PTCT to rise to within 12 months (a possible 9.23% upside). 38 analyst firms have reported ratings in the last year.

The latest analyst rating for PTC Therapeutics (NASDAQ:PTCT) was provided by Jefferies, and PTC Therapeutics downgraded their hold rating.

The last upgrade for PTC Therapeutics Inc happened on January 28, 2026 when Barclays raised their price target to $119. Barclays previously had an equal-weight for PTC Therapeutics Inc.

The last downgrade for PTC Therapeutics Inc happened on March 30, 2026 when Jefferies changed their price target from $91 to $76 for PTC Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PTC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PTC Therapeutics was filed on March 30, 2026 so you should expect the next rating to be made available sometime around March 30, 2027.

While ratings are subjective and will change, the latest PTC Therapeutics (PTCT) rating was a downgraded with a price target of $91.00 to $76.00. The current price PTC Therapeutics (PTCT) is trading at is $69.58, which is out of the analyst’s predicted range.